Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -55.61%60.88M | -70.31%9.6M | -86.04%4.77M | -57.96%15.09M | -9.63%31.43M | 12.83%137.14M | -10.79%32.32M | -5.56%34.16M | 28.14%35.89M | 64.49%34.78M |
Operating revenue | -55.61%60.88M | -70.31%9.6M | -86.04%4.77M | -57.96%15.09M | -9.63%31.43M | 12.83%137.14M | -10.79%32.32M | -5.56%34.16M | 28.14%35.89M | 64.49%34.78M |
Cost of revenue | -25.91%75.21M | -16.27%20.83M | -46.78%12.6M | -28.35%18.53M | -14.16%23.25M | -6.08%101.5M | -15.68%24.88M | -30.86%23.68M | 0.18%25.86M | 46.33%27.08M |
Gross profit | -140.19%-14.32M | -250.93%-11.23M | -174.73%-7.83M | -134.34%-3.44M | 6.34%8.18M | 164.62%35.64M | 10.67%7.44M | 445.64%10.48M | 357.59%10.03M | 192.16%7.69M |
Operating expense | 63.66%27.46M | 8.68%7.15M | 90.27%6.45M | 94.42%7.43M | 115.12%6.43M | 30.63%16.78M | 106.27%6.58M | 15.54%3.39M | 25.82%3.82M | -18.85%2.99M |
Selling and administrative expenses | 67.33%26.29M | 8.44%6.84M | 97.45%6.17M | 100.82%7.14M | 125.50%6.14M | 31.91%15.71M | 116.02%6.31M | 18.77%3.12M | 24.95%3.56M | -22.47%2.72M |
-Selling and marketing expense | -28.69%109K | 347.79%66.8K | -83.89%14.35K | -33.17%11.05K | -48.03%16.81K | -41.07%152.85K | -83.18%14.92K | 156.62%89.07K | -68.53%16.53K | -62.68%32.34K |
-General and administrative expense | 68.28%26.18M | 7.63%6.77M | 102.77%6.15M | 101.44%7.13M | 127.59%6.12M | 33.54%15.56M | 122.25%6.29M | 16.92%3.03M | 26.70%3.54M | -21.45%2.69M |
Depreciation amortization depletion | 9.51%1.17M | 14.38%304.28K | 6.03%282.07K | 8.81%289.47K | 8.81%289.47K | 14.22%1.06M | -0.39%266.03K | -12.40%266.03K | 38.87%266.03K | 55.51%266.02K |
-Depreciation and amortization | 9.51%1.17M | 14.38%304.28K | 6.03%282.07K | 8.81%289.47K | 8.81%289.47K | 14.22%1.06M | -0.39%266.03K | -12.40%266.03K | 38.87%266.03K | 55.51%266.02K |
Operating profit | -321.48%-41.78M | -2,221.49%-18.38M | -301.38%-14.28M | -275.35%-10.88M | -62.77%1.75M | 2,913.55%18.87M | -75.50%866.25K | 800.47%7.09M | 831.83%6.2M | 548.04%4.71M |
Net non-operating interest income expense | 24.69%-448.81K | -130.87%-270.22K | 154.26%70.72K | 25.31%-116.72K | 31.06%-132.58K | 69.57%-595.98K | 76.29%-117.05K | 81.15%-130.34K | 74.13%-156.27K | -13.37%-192.33K |
Non-operating interest income | --105.4K | ---78.14K | --183.54K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
Non-operating interest expense | -7.01%554.2K | 64.11%192.08K | -13.44%112.81K | -25.31%116.72K | -31.06%132.58K | -69.57%595.98K | -76.29%117.05K | -81.15%130.34K | -74.13%156.27K | 13.37%192.33K |
Other net income (expense) | -859.16%-836.62K | -9,969.19%-1.44M | -234.32%-69.71K | 6,010.14%654.58K | -51.09%16.15K | -85.86%110.2K | -95.10%14.57K | 198.97%51.89K | -98.09%10.71K | 231.16%33.03K |
Gain on sale of security | --369.16K | --244.24K | --124.92K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Earnings from equity interest | -69.27%33.86K | --0 | --0 | 65.32%17.71K | -51.09%16.15K | 223.71%110.2K | 131.00%14.57K | 198.97%51.89K | -69.84%10.71K | 231.16%33.03K |
Special income (charges) | ---1.88M | ---1.68M | ---194.86K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
-Less:Impairment of capital assets | --1.18M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
-Less:Other special charges | --194.86K | --1 | --194.86K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Write off | --498.27K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | --636.87K | ---239 | --239 | --636.87K | ---- | ---- | ---- | ---- | ---- | ---- |
Income before tax | -334.32%-43.07M | -2,729.76%-20.09M | -303.61%-14.28M | -270.68%-10.34M | -64.02%1.64M | 3,422.25%18.38M | -77.13%763.77K | 499.30%7.01M | 779.07%6.06M | 465.13%4.55M |
Income tax | 226.71%2.87M | 95.58%-100K | 0 | 2.55M | 423K | -2.27M | -2.27M | 0 | 0 | 0 |
Net income | -322.52%-45.94M | -759.85%-19.99M | -303.61%-14.28M | -312.73%-12.89M | -73.33%1.21M | 3,831.66%20.64M | -9.32%3.03M | 499.30%7.01M | 779.07%6.06M | 465.13%4.55M |
Net income continuous Operations | -322.52%-45.94M | -759.85%-19.99M | -303.61%-14.28M | -312.73%-12.89M | -73.33%1.21M | 3,831.66%20.64M | -9.32%3.03M | 499.30%7.01M | 779.07%6.06M | 465.13%4.55M |
Minority interest income | -880.82%-208.55K | -2,400.77%-172.56K | 93.82%-4.4K | -121.36%-19.43K | -2,011.81%-12.16K | -79.06%26.71K | -97.46%7.5K | 67.08%-71.17K | 12.16%90.96K | 98.24%-576 |
Net income attributable to the parent company | -321.79%-45.73M | -755.77%-19.81M | -301.51%-14.28M | -315.65%-12.87M | -73.06%1.22M | 3,128.65%20.62M | -0.77%3.02M | 559.96%7.08M | 713.13%5.97M | 475.01%4.55M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -321.79%-45.73M | -755.77%-19.81M | -301.51%-14.28M | -315.65%-12.87M | -73.06%1.22M | 3,128.65%20.62M | -0.77%3.02M | 559.96%7.08M | 713.13%5.97M | 475.01%4.55M |
Basic earnings per share | -264.83%-2.39 | -585.71%-1.02 | -246.00%-0.73 | -257.14%-0.66 | -78.13%0.07 | 3,000.00%1.45 | -16.00%0.21 | 516.67%0.5 | 625.00%0.42 | 420.00%0.32 |
Diluted earnings per share | -273.19%-2.39 | -636.84%-1.02 | -248.98%-0.73 | -265.00%-0.66 | -77.42%0.07 | 2,860.00%1.38 | -24.00%0.19 | 508.33%0.49 | 600.00%0.4 | 410.00%0.31 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |